Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBT Margin (2021 - 2025)

Kiniksa Pharmaceuticals International's EBT Margin history spans 5 years, with the latest figure at 31.08% for Q4 2025.

  • For Q4 2025, EBT Margin fell 4047.0% year-over-year to 31.08%; the TTM value through Dec 2025 reached 0.41%, up 222.0%, while the annual FY2025 figure was 0.41%, 222.0% up from the prior year.
  • EBT Margin reached 31.08% in Q4 2025 per KNSA's latest filing, down from 15.02% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 684.08% in Q4 2021 to a low of 526.34% in Q2 2021.
  • Average EBT Margin over 5 years is 9.38%, with a median of 6.42% recorded in 2024.
  • The largest YoY upside for EBT Margin was 45491bps in 2022 against a maximum downside of -74538bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 684.08% in 2021, then crashed by -109bps to 61.3% in 2022, then surged by 283bps to 112.22% in 2023, then tumbled by -92bps to 9.38% in 2024, then plummeted by -431bps to 31.08% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's EBT Margin are 31.08% (Q4 2025), 15.02% (Q3 2025), and 14.59% (Q2 2025).